Sign In
Buy MTNB
$0.294
-0.0236 (-7.44%)
At Close: Jul 31, 2026
MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024
09:56pm, Thursday, 09'th May 2024
Matinas BioPharma Hldgs (NYSEMKT: MTNB ) just reported results for the first quarter of 2024. Matinas BioPharma Hldgs reported earnings per share of -3 cents.
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
07:47pm, Thursday, 09'th May 2024
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer T
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
04:05pm, Thursday, 09'th May 2024
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies usi
Matinas BioPharma Prices $10 Million Registered Direct Offering
08:30am, Wednesday, 03'rd Apr 2024
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
11:20pm, Thursday, 28'th Mar 2024
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
04:05pm, Wednesday, 27'th Mar 2024
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
08:00am, Monday, 25'th Mar 2024
Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies u
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
06:30am, Friday, 22'nd Mar 2024
BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies u
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
07:30am, Thursday, 21'st Dec 2023
Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
10:44pm, Wednesday, 08'th Nov 2023
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Fergu
Penny Stocks To Buy Now? 3 to Watch With Big News
09:26am, Tuesday, 07'th Nov 2023
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
